These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 37939861)
1. Identification of benzothiazoles as novel PCSK9 inhibitors. Ma Z; Liu H; Jiang S; Li W; Li Y; Liu Y; Wang L; Li W Bioorg Med Chem Lett; 2024 Jan; 97():129542. PubMed ID: 37939861 [TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686 [TBL] [Abstract][Full Text] [Related]
3. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. Wang Y; Liu ZP Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249 [TBL] [Abstract][Full Text] [Related]
4. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867 [TBL] [Abstract][Full Text] [Related]
10. PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective. Momtazi-Borojeni AA; Pirro M; Xu S; Sahebkar A Curr Med Chem; 2022; 29(6):980-999. PubMed ID: 34711156 [TBL] [Abstract][Full Text] [Related]
11. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]. Scheen AJ; Wallemacq C; Lancellotti P Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754 [TBL] [Abstract][Full Text] [Related]
12. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of anti-PCSK9 antibodies: Results from recent trials. Gouni-Berthold I Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. Bittner VA; Giugliano RP; Brinton EA; Guyton JR J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750 [TBL] [Abstract][Full Text] [Related]
16. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction. Smith KW; White CM J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. McDonagh M; Peterson K; Holzhammer B; Fazio S J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792 [TBL] [Abstract][Full Text] [Related]
18. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
19. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841 [TBL] [Abstract][Full Text] [Related]